Haematological toxicity of drugs used in psychiatry

Human Psychopharmacology

Volumn 23, Issue SUPPL. 1, 2008, Pages 27-41

  Flanagan, Robert J ^a   Dunk, Louisa ^b  

^a KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^b LEICESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

Agranulocytosis; Blood dyscrasia; Clozapine; Drug induced; Neutropenia; Neutropenia agranulocytosis; Psychotropic medication

Indexed keywords

AMISULPRIDE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CHLORPROMAZINE; CLOZAPINE; CYTOTOXIC AGENT; DENZAPINE; DESIPRAMINE; IMIPRAMINE; LITHIUM; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; PHENOTHIAZINE DERIVATIVE; PSYCHOTROPIC AGENT; QUETIAPINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SULPIRIDE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; ZAPONEX; ZIDOVUDINE; ZIPRASIDONE;

AGRANULOCYTOSIS; ANEMIA; APLASTIC ANEMIA; BIPOLAR DISORDER; BLEEDING; BLOOD CELL COUNT; BLOOD DYSCRASIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG METABOLISM; DRUG RECHALLENGE; DRUG SAFETY; DRUG STRUCTURE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EOSINOPHILIA; ERYTHROCYTE APLASIA; ERYTHROCYTE COUNT; EVIDENCE BASED MEDICINE; FEVER; GASTROINTESTINAL HEMORRHAGE; HEMOLYTIC ANEMIA; HEREDITY; HIGH RISK POPULATION; HUMAN; IMMUNOPATHOGENESIS; INFECTION; LABORATORY TEST; LEUKEMIA; LEUKOCYTOSIS; LEUKOPENIA; LYMPHOCYTOPENIA; MENTAL DISEASE; MONOCYTOSIS; MONOTHERAPY; MORTALITY; NEUROLEPTIC MALIGNANT SYNDROME; NEUTROPENIA; NEUTROPHIL COUNT; PANCYTOPENIA; PATHOPHYSIOLOGY; PATIENT CARE; PATIENT COMPLIANCE; PATIENT MONITORING; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; SCHIZOPHRENIA; SIDE EFFECT; SKIN BRUISING; SOLID TUMOR; THROMBOCYTE DISORDER; THROMBOCYTOPENIA; THROMBOCYTOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT DURATION;

ANIMALS; HEMATOLOGIC DISEASES; HUMANS; MENTAL DISORDERS; PSYCHOTROPIC DRUGS;

EID: 38649101300     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.917     Document Type: Review

References (97)

1. Acharya S, Bussel JB. 2000. Hematologic toxicity of sodium valproate. J Pediatr Hematol Oncol 22: 62-65.
2. Ahn YM, Jeong SH, Jang HS, et al. 2004. Experience of maintaining clozapine medication in patients with 'red-alert zone' neutropenia: long-term follow-up results. Int Clin Psychopharmacol 19: 97-101.
3. Ahokas A, Elonen E. 1999. Circadian rhythm of white blood cells during clozapine treatment. Psychopharmacol (Berl) 144: 301-302.
4. Alvir JM, Lieberman JA, Safferman AZ, Schwimmer JL, Schaaf JA. 1993. Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. N Engl J Med 329: 162-167.
5. Alvir JM, Lieberman JA, Safferman AZ. 1995. Do white-cell count spikes predict agranulocytosis in clozapine recipients? Psychopharmacol Bull 31: 311-314.
6. Anderson R, Walters L, Grabow G, van der Merwe M, van Rensburg CE. 1982. The effects of lithium on the functions of human neutrophils and lymphocytes in vitro and in vivo. S Afr Med J 62: 519-523.
7. Andrès E, Noel E, Kurtz JE, Henoun Loukili N, Kaltenbach G, Maloisel F 2004. Life-threatening idiosyncratic drug-induced agranulocytosis in elderly patients. Drugs Aging 21: 427-435.
8. Atkin K, Kendall F, Gould D, Freeman H, Liberman J, O'Sullivan D. 1996. Neutropenia and agranulocytosis in patients receiving clozapine in the UK and Ireland. Br J Psychiatr 169: 483-488.
9. Banov MD, Tohen M, Friedberg J. 1993. High risk of eosinophilia in women treated with clozapine. J Clin Psychiatr 54: 466-469.
10. Berliner N, Horwitz M, Loughran TP. 2004. Congenital and acquired neutropenia. Hematology 2004. Am Soc Hematol Educ Program 63-79.
11. Bhatt V, Saleem A. 2004. Review: drug-induced neutropenia-pathophysiology, clinical features, and management. Ann Clin Lab Sci 34: 131-137.
12. Blackburn SC, Oliart AD, García Rodríguez LA, Pérez; Gutthann S. 1998. Antiepileptics and blood dyscrasias: a cohort study. Pharmacotherapy 18: 1277-1281
13. Boshes RA, Manschreck TC, Desrosiers J, Candela S, Hanrahan-Boshes M. 2001. Initiation of clozapine therapy in a patient with preexisting leucopenia: a discussion of the rationale of current treatment options. Ann Clin Psychiatr 13: 233-237. (Erratum) 14: 141.
14. Brewerton TD. 1986. Lithium counteracts carbamazepine-induced leukopenia while increasing its therapeutic effect. Biol Psychiatr 21: 677-685.
15. Burckart GJ, Snidow J, Bruce W. 1981. Neutropenia following acute chlorpromazine ingestion. Clin Toxicol 18: 797-801.
16. Chatterton R. 1997. Eosinophilia after commencement of clozapine treatment. Aust N Z J Psychiatr 31: 874-876.
17. Conus P, Nanzer N, Baumann R 2001. An alternative to interruption of treatment in recurrent clozapine-induced severe Deutropenia. Br J Psychiatr 179: 180.
18. Copolov DL, Bell WR, Benson WJ, Keks NA, Strazzeri DC, Johnson GE 1998. Clozapine treatment in Australia: a review of haermatological monitoring. Med J Aust 168: 495-497.
19. Cordes J, Streit M, Loeffler S, von Wilmsdorff M, Agelink M, Klimke A. 2004. Reversible neutropenia during treatment with olanzapine: three case reports. World J Biol Psychiatr 5: 230-234.
20. Cowan C, Oakley C. 2007. Leucopenia and neutropenia induced by quetiapine. Prog Neuropsychopharmacol Biol Psychiatr 31: 292-294.
21. Croarkin P, Rayner T. 2001. Acute neutropenia in a patient treated with quetiapine. Psychosomatics 42: 368.
22. Delieu JM, Badawoud M, Williams MA, Horobin RW, Duguid JK. 2001. Antipsychotic drugs result in the formation of immature neutrophil leucocytes in schizophrenic patients. J Psychopharmacol 15: 191-194.
23. Delieu JM, Horobin RW, Duguid JK. 2006. Formation of immature neutrophil leucocytes in schizophrenic patients treated with various antipsychotic drugs: comparisons and predictions. J Psychopharmacol 20: 824-828.
24. 4502 D6. Pharmacopsychiatry 33: 218-220.
25. Duggal HS, Singh I. 2005. Psychatropic drug-induced neutropenia. Drugs Today (Barc) 41: 517-526.
26. Duggal HS, Gates C, Pathak PC. 2004. Olanzapine-induced neutropenia: mechanism and treatment. J Clin Psychopharmacol 24: 234-235.
27. Dunk LR, Annan LJ, Andrews CD. 2006. Rechallenge with clozapine following leucopenia or neutropenia during previous therapy. Br J Psychiatr 188: 255-263.
28. Esposito D, Aouillé J, Rouillon F, Limosin F. 2004. Two year follow-up of a patient with successful continuation of clozapine treatment despite morning pseudoneutropenia. J Clin Psychiatr 65: 1281.
29. Esposito D, Corruble E, Hardy P, Chouinard G. 2005a. Risperidone-induced morning pseudoneutropenia. Am J Psychiatr 162: 397.
30. Esposito D, Rouillon F, Limosin F. 2005b. Continuing clozapine treatment despite neutropenia. Eur J Clin Pharmacol 60: 759-764.
31. Esposito D, Chouinard G, Hardy P, Corruble E. 2006. Successful initiation of clozapine treatment despite morning pseudoneutropenia. Int J Neuropsychopharmacol 9: 489-4491.
32. Fitzsimons J, Berk M, Lambert T, Bourin M, Dodd S. 2005. A review of clozapine safety, Expert Opin Drug Saf 4: 731-744.
33. Gardner I, Popovic M, Zahid N, Uetrecht JP. 2005. A comparison of the covalent binding of clozapine, procainamide, and vesnarinone to human neutrophils in vitro and rat tissues in vitro and in vivo. Chem Res Toxicol 18: 1384-1394.
34. Gerbino-Rosen G, Roofeh D, Tompkins DA, et al. 2005. Hematological adverse events in clozapine-treated children and adolescents. J Am Acad Child Adolesc Psychiatr 44: 1024-1031.
35. Gerson SL. 1994. G-CSF and the management of clozapine-induced agranulocytosis. J Clin Psychiatr 55 (Suppl. B): 139-142.
36. Gillman K. 2000. Paradoxical pattern of haematological risk with clozapine. Br J Psychiatr 177: 88.
37. Gomez-Estrada H, Hemandez-Delgado J, Diaz-Esquivel P. 1984. Decreased myeloperoxidase activity of mice polymorphonuclear leukocytes by lithium carbonate treatment. Arch Invest Med (Mex) 15: 287-291.
38. Hagg S, Rosenius S, Spigset O. 2003. Long-term combination treatment with clozapine and filgrastim in patients with clozapine-induced agranulocytosis. Int Clin Psychopharmacol 18: 173-174.
39. Hall RL, Smith AG, Edwards JG. 2003. Haematological safety of antipsychotic drugs. Expert Opinion Drug Saf 2: 395-399.
40. Halperin D, Reber G. 2007. Influence of antidepressants on hemostasis. Dialogues Clin Neurosci 9: 47-59.
41. Hasegawa M, Cola PA, Meltzer HY. 1994. Plasma clozapine and desmethylclozapine levels in clozapine-induced agranulocytosis. Neuropsychopharmacology 11: 45-47.
42. Honigfeld G, Arellano F, Sethi J, Bianchini A, Schein J. 1998. Reducing clozapine-related morbidity and mortality: 5 years of experience with the Clozaril National Registry. J Clin Psychiatr 59 (Suppl 3): 3-7.
43. Hsuanyu Y, Dunford HB. 1999. Oxidation of clozapine and ascorbate by myeloperoxidase. Arch Biochem Biophys 368: 413-420.
44. Hummer M, Kurz M, Barnas C, Saria A, Fleischhacker WW. 1994. Clozapine-induced transient white blood count disorders. J Clin Psychiatr 55: 429-432.
45. Husain Z, Almeciga I, Delgado JC, et al. 2006. Increased FasL expression correlates with apoptotic changes in granulocytes cultured with oxidized clozapine. Toxicol Appl Pharmacol 214: 326-334.
46. Huynh M, Chee K, Lau DH. 2005. Thrombotic thrombocytopenic purpura associated with quetiapine. Ann Pharmacother 39: 1346-1349.
47. Imbarlina MJ, Sarkar S, Marwah S, et al. 2004. Leucopenia in clozapine treated patients may be induced by other drugs: a case series. Eur Psychiatr 19: 506-509.
48. Jauss M, Pantel J, Werle E, Schroder J. 2000. G-CSF plasma levels in clozapine-induced neutropenia. Biol Psychiatr 48: 1113-1115.
49. Kanaan RA, Kerwin RW. 2006. Lithium and clozapine rechallenge: a retrospective case analysis. J Clin Psychiatr 67: 756-760.
50. Kang BJ, Cho MJ, Oh JT, Lee Y, Chae BJ, Ko J. 2006. Long-term patient monitoring for clozapine-induced agranutocytosis and neutropenia in Korea: when is it safe to discontinue CPMS? Hum Psychopharmacol 21: 387-391.
51. Kelly DL, Kreyenbuhl J, Dixon L, Love RC, Medoff D, Conley RR. 2007. Clozapine underutilization and discontinuation in African Americans due to leucopenia. Schizophr Bull 33: 1221-1224.
52. Kerwin RW, Osborne S, Sainz-Fuertes R. 2004. Heat stroke in schizophrenia during clozapine treatment: rapid recognition and management. J Psychopharmacol 18: 121-123.
53. King DJ, Wager E. 1998. Haematological safety of antipsychotic drugs. J Psychopharmacol 12: 283-288.
54. Kortner K, Neuhaus AH, Schurer F, Dettling M. 2007. Eosinophilia indicating subclinical clozapine-induced pericarditis. J Clin Psychiatr 68: 1147-1148.
55. Lamberti JS, Bellnier TJ, Schwarzkopf SB, Schneider E. 1995. Filgrastim treatment of three patients with clozapine-induced agranulocytosis. J Clin Psychiatr 56: 256-259.
56. Levin GM, DeVane CL. 1992. A review of cyclic antidepressant-induced blood dyscrasias. Ann Pharmacother 26: 378-383.
57. Martin KA, Krahn LE, Balan V, Rosati MJ. 2007. Selective serotonin reuptake inhibitors in the context of hepatitis C infection: reexamining the risks of bleeding. J Clin Psychiatr 68: 1024-1026.
58. Meged S, Stein D, Sitrota P, et al. 1999. Human leucocyte antigen typing, response to neuroleptics, and clozapine-induced agranulocytosis in jewish Israeli schizophrenic patients. Int Clin Psychopharmacol 14: 305-312.
59. Meltzer HY, Davidson M, Glassman AH, Vieweg WV. 2002. Assessing cardiovascular risks versus clinical benefits of atypical antipsychotic drug treatment. J Clin Psychiatr 63 (Suppl 9): 25-29.
60. Montgomery J. 2006. Ziprasidone-related agranulocytosis following olanzapine-induced neutropenia. Gen Hosp Psychiatr 28: 83-85.
61. Mosyagin I, Dettling M, Roots I, Mueller-Oerlinghausen B, Cascorbi I. 2004. Impact of myeloperoxidase and NADPH-oxidase polymorphisms in drug-induced agranulocytosis. J Clin Psychopharmacol 24: 613-617.
62. Munro J, O'Sullivan D, Andrews C, Arana A, Mortimer A, Kerwin R. 1999. Active monitoring of 12,760 clozapine recipients in the UK and Ireland. Beyond pbarmacovigilance. Br J Psychiatr 175: 576-580.
63. Murry P, Laurent A. 2001. Is it possible to distinguish between benign and malignant neutropenia in clozapine-treated patients by means of a hydrocortisone test? Psychopharmacol (Berl) 158: 329-330.
64. Nielsen H. 1993. Recombinant human granulocyte colony-stimulating factor (rhG-CSF; filgrastim) treatment of clozapine-induced agranulocytosis. J Intern Med 234: 529-531.
65. Oyesanmi O, Kunkel EJ, Monti DA, Field HL. 1999. Hematologic side effects of psychotropics. Psychosomatics 40: 414-421.
66. Ozdemir MA, Sofuoglu S, Tanrikulu G, Aldanmaz F, Esel E, Dundar S. 1994. Lithium-induced hematologic changes in patients with bipolar affective disorder. Biol Psychiatry 35: 210-213.
67. Pantelis C, Adesanya A. 2001. Increased risk of neutropaenia and agranulocytosis with sodium valproate used adjunctively with clozapine. Aust N Z J Psychiatr 35: 544-545.
68. Patel NC, Dorson PG, Bettinger TL. 2002. Sudden late onset of clozapine-induced agranulocytosis. Ann Pharmacother 36: 1012-1015.
69. Patel NC, Crismon ML, Miller AL, Johnsrud MT. 2005. Drug adherence: effects of decreased visit frequency on adherence to clozapine therapy. Pharmacotherapy 25: 1242-1247.
70. Paton C, Esop R. 2005. Managing clozapine-induced neutropenia with lithium. Psychiatr Bull 29: 186-188.
71. Pereira A, Dean B. 2006. Clozapine bioactivation induces dose-dependent, drug-specific toxicity of human bone marrow stromal cells: a potential in vitro system for the study of agranulocytosis. Biochem Pharmacol 72: 783-793.
72. Perucca E. 2002. Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs 16: 695-714.
73. Pessina A, Turlizzi E, Bonomi A, et al. 2006. In vitro toxicity of clozapine, olanzapine, and quetiapine on granulocyte-macrophage progenitors (GM-CFU). Pharmacopsychiatry 39: 20-22; 39: 160.
74. Pirmohamed M, Park K. 1997. Mechanism of clozapine-induced agranulocytosis. Current status of research and implications for drug development. CNS Drugs 7: 139-158.
75. Pope HG, Cole JO, Choras PT, Fulwiler CE. 1986. Apparent neuroleptic malignant syndrome with clozapine and lithium. J Nerv Ment Dis 174: 493-495.
76. Porter R, Mohamed A. 2006. Diurnal variation of neutropenia during clozapine treatment. Int J Neuropsychopharmacol 9: 373-374.
77. Rajagopal S. 2005. Clozapine, agranulocytosis, and benign ethnic neutropenia. Postgrad Med J 81: 545-546.
78. Reeves RR, Wise PM, Cox SK. 2007. SSRIs & the risk of abnormal bleeding. J Psychosoc Nurs Ment Health Serv 45: 15-21.
79. Sayin A, Cosar B. 2006. Prolongation of clozapine-induced leucopenia with olanzapine treatment. Prog Neuropsychopharmacol Biol Psychiatr 30: 958-959.
80. Sedky K, Lippmarm S. 2006. Psychotropic medications and leucopenia. Curr Drug Targets 7: 1191-1194.
81. Serebruany VL. 2006. Selective serotonin reuptake inhibitors and increased bleeding risk: are we missing something? Am J Med 119: 113-116.
82. Shoenfeld Y, Alkan ML, Asaly A, Carmeli Y, Katz M. 1988. Benign familial leucopenia and neutropenia in different ethnic groups. Eur J Haematol 41: 273-277.
83. Silvestrini C, Arcangeli T, Biondi M, Pancheri P. 2000. A second trial of clozapine in a case of granulocytopenia. Hum Psychopharmacol 15: 275-279.
84. Sluys M, Guzelcan Y, Casteelen G, de Haan L. 2004. Risperidone-induced leucopenia and neutropenia: a case report. Eur Psychiatr 19: 117.
85. Sporn A, Gogtay N, Ortiz-Aguayo R, et al. 2003. Clozapine-induced neutropenia in children: management with lithium carbonate. J Child Adolesc Psychopharmacol 13: 401-404.
86. Stergiou V, Bozikas VP, Garyfallos G, Nikolaidis N, Lavrentiadis G, Fokas K. 2005. Olanzapine-induced leucopenia and neutropenia. Prog Neuropsychopharmacol Biol Psychiatr 29: 992-994.
87. Stip E, Langlois R, Thuot C, Mancini-Marie A. 2007. Fatal agranulocytosis: the use of olanzapine in a patient with schizophrenia and myelodysplasia. Prog Neuropsychopharmacol Biol Psychiatr 31: 297-300.
88. Stüter S, Grohmann R, Engel R, et al. 2004. Blood dyscrasias induced by psychotropic drugs. Pharmacopsychiatry 37 (Suppl 1): S70-S78.
89. Thangadurai P, Jyothi KS, Gopalakrishnan R, Kuruvilla A, Jacob KS. 2006. Reversible neutropenia with olanzapine following clozapine-induced neutropenia. Am J Psychiatr 163: 1298.
90. Tohen M, Castillo J, Baldessarini RJ, Zarate C, Kando JC. 1995. Blood dyscrasias with carbamazepine and valproate: a pharmacoepidemiological study of 2,228 patients at risk. Am J Psychiatr 152: 413-418.
91. Turkozkan N, Durmus O, Boran N. 1993. Biochemical investigation of leukocyte functions during lithium therapy. Int J Biochem 25: 1501-1504.
92. Valevski A, Mein T, Gazit E, et al. 1998. HLA-B38 and clozapine-induced agranulocytosis in Israeli Jewish schizophrenic patients. Eur J Immunogenet 25: 11-13.
93. Vesta KS, Medina PJ. 2003. Valproic acid-induced neutropenia. Ann Pharmacother 37: 819-821.
94. Vieweg WVR, Yank GR, Row WT, Hovermale LS. 1986. Increase in white blood cell count and serum sodium level following the addition of lithium to carbamazepine treatment among three chronically psychotic male patients with disturbed affective states. Psychiatr Q 58: 213-217.
95. Wessinger S, Kaplan M, Choi L, et al. 2006. Increased use of selective serotonin reuptake inhibitors in patients admitted with gastrointestinal haemorrhage: a multicentre retrospective analysis. Aliment Pharmacol Ther 23: 937-944.
96. Whiskey E, Taylor D. 2007. Restarting clozapine after neutropenia: evaluating the possibilities and practicalities. CNS Drugs 21: 25-35.
97. Yen CF, Chong MY, Kuo MC, Chang CS. 1997. Severe granulocytopenia secondary to chlorpromazine despite concurrent lithium treatment: a case report. Kaohsiung J Med Sci 13: 635-638.